AstraZeneca Pharma India Limited

NSE: ASTRAZEN · Unclassified

₹6,373.50+1.26%06 Nov 2026

Ask the data

Instant answers about AstraZeneca Pharma India Limited — computed from its filings, no language model

Market cap₹15,934 cr

Current price₹6,373.50

High / Low₹9,828 / ₹5,720

P/E89.7

P/B18.13

Book value₹351.6

ROE20.2%

ROCE28.5%

Debt / equity0.00

Dividend yield0.50%

EPS (TTM)₹71.09

Face value₹2

Price & valuation

split & bonus adjusted · pick a metric and range

Annual performance

annual · ₹ crore · line = operating margin

showing latest 6 of 8 periods

	FY19	FY20	FY21	FY22	FY23	FY24	FY25	FY26
Revenue	728	832	814	806	1,003	1,296	1,716	2,276
EBITDA	71	121	135	86	165	184	254	262
Operating margin	9.8%	14.5%	16.7%	10.7%	16.5%	14.2%	14.8%	11.5%
Interest	0	1	1	1	1	1	1	4
Depreciation	15	19	20	17	16	15	40	29
Profit before tax	73	114	127	83	134	220	156	252
Tax	18	42	34	21	35	58	41	65
Net profit	0	72	93	62	99	162	116	188
EPS ₹	21.78	28.88	37.32	24.64	39.72	64.60	46.30	75.01
Operating cash flow	—	—	—	101	58	93	65	-15
Capex	—	—	—	10	9	11	2	4
Dividend paid	—	—	—	5	20	40	60	80
Total assets	—	—	—	—	985	1,078	1,518	1,989
Equity	—	—	—	—	589	712	770	873

Quarterly performance

last 36 quarters · ₹ crore

showing latest 8 of 36 periods

	MAR '17	MAR '18	JUN '18	SEP '18	DEC '18	MAR '19	JUN '19	SEP '19	DEC '19	MAR '20	JUN '20	SEP '20	DEC '20	MAR '21	JUN '21	SEP '21	DEC '21	MAR '22	JUN '22	SEP '22	DEC '22	MAR '23	JUN '23	SEP '23	DEC '23	MAR '24	JUN '24	SEP '24	DEC '24	MAR '25	JUN '25	SEP '25	DEC '25	MAR '26	JUN '26	SEP '26
Revenue	117	151	161	161	215	190	205	208	224	195	194	209	200	210	175	198	201	232	232	236	250	285	295	311	306	383	388	408	440	480	526	559	612	579	683	729
Operating profit	1	15	9	15	41	6	36	34	37	15	29	36	31	40	16	18	15	38	28	41	37	60	67	53	15	49	38	53	77	86	81	75	45	61	49	96
Operating margin	0.6%	10.1%	5.7%	9.1%	19.0%	3.3%	17.4%	16.1%	16.4%	7.6%	14.8%	17.1%	15.4%	19.2%	8.9%	9.1%	7.3%	16.4%	12.0%	17.2%	14.6%	21.0%	22.8%	17.0%	4.9%	12.9%	9.8%	12.9%	17.5%	18.0%	15.4%	13.4%	7.3%	10.5%	7.2%	13.1%
Other income	1	2	3	3	4	6	3	3	3	3	3	5	3	3	3	3	5	4	4	7	7	8	8	8	10	9	8	8	8	16	11	6	5	6	9	15
Interest	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	-0	0	0	0	1	1	1	1	2	2	2
Depreciation	4	4	4	4	4	4	5	5	5	5	5	5	5	6	5	4	4	4	5	3	4	4	4	4	4	4	4	9	9	18	17	3	4	6	5	5
Profit before tax	-2	14	9	14	41	8	34	32	35	13	26	36	28	37	14	16	16	37	27	44	39	23	71	73	20	54	-15	51	42	78	75	73	47	58	51	88
Tax	8	11	3	5	12	-1	12	17	8	4	8	9	7	10	3	4	5	9	7	12	10	6	18	21	5	15	-3	13	11	20	19	19	14	13	13	26
Net profit	0	0	0	0	0	0	0	14	27	10	19	26	21	27	10	12	11	28	20	33	29	17	54	52	16	39	-12	38	31	58	56	54	33	45	38	62
EPS ₹	-3.82	1.29	2.56	3.65	11.64	3.93	8.61	5.77	10.68	3.83	7.45	10.54	8.42	10.91	4.10	4.78	4.57	11.19	8.06	13.03	11.72	6.91	21.54	20.95	6.32	15.79	-4.72	15.37	12.34	23.30	22.33	21.69	13.04	17.95	15.17	24.93
Revenue YoY	—	29.0%	—	—	—	26.3%	26.7%	29.2%	4.0%	2.4%	-5.4%	0.5%	-10.5%	7.9%	-9.4%	-5.6%	0.1%	10.3%	32.5%	19.4%	24.6%	22.7%	27.2%	31.7%	22.4%	34.6%	31.2%	31.2%	44.0%	25.4%	35.8%	37.0%	38.9%	20.4%	29.7%	30.4%
Profit YoY	—	—	—	—	—	—	—	—	—	—	—	82.7%	-21.2%	184.8%	-45.0%	-54.6%	-45.7%	2.6%	96.8%	172.5%	156.6%	-38.3%	167.3%	60.8%	-46.1%	128.6%	-121.9%	-26.6%	95.3%	47.5%	—	41.1%	5.6%	-23.0%	-32.1%	15.0%

Earlier results (standalone, Sep '07 – Dec '16)

₹ crore · from BSE, before the NSE XBRL filings begin

AstraZeneca Pharma India Limited reports consolidated figures above. Quarterly consolidated results only became mandatory in India in 2019, so the earlier history available is the standalone company only (excluding subsidiaries). It is shown separately so the two bases are never mixed.

Full years

	FY09†	FY10†	FY11†	FY12†	FY13†	FY14†	FY15†	FY16†
Revenue	356	414	496	531	390	474	517	564
Operating profit	101	83	99	30	-68	-13	-11	16
Operating margin	28.4%	20.0%	19.9%	5.7%	-17.5%	-2.7%	-2.2%	2.9%
Other income	19	4	6	6	10	9	6	7
Interest	4	—	—	—	—	—	—	—
Depreciation	7	6	7	7	12	10	15	17
Profit before tax	109	80	97	29	-70	0	-21	6
Tax	39	28	35	9	19	1	0	0
Net profit	70	53	62	20	-90	-1	-21	5

Quarters

showing latest 8 of 38 periods

	SEP '07†	DEC '07†	MAR '08†	JUN '08†	SEP '08†	DEC '08†	MAR '09†	JUN '09†	SEP '09†	DEC '09†	MAR '10†	JUN '10†	SEP '10†	DEC '10†	MAR '11†	JUN '11†	SEP '11†	DEC '11†	MAR '12†	JUN '12†	SEP '12†	DEC '12†	MAR '13†	JUN '13†	SEP '13†	DEC '13†	MAR '14†	JUN '14†	SEP '14†	DEC '14†	MAR '15†	JUN '15†	SEP '15†	DEC '15†	MAR '16†	JUN '16†	SEP '16†	DEC '16†
Revenue	73	82	70	88	90	97	80	99	101	116	98	111	126	133	127	137	149	153	92	91	99	105	95	125	116	119	114	126	115	108	169	132	128	145	159	140	138	150
Operating profit	23	29	13	28	29	33	11	24	20	34	5	12	27	43	17	25	32	22	-49	-19	-20	-15	-14	1	-2	3	-15	-16	-26	-10	41	5	-4	12	3	16	3	15
Operating margin	32.0%	35.3%	18.9%	31.7%	32.5%	33.8%	13.5%	24.6%	19.5%	29.2%	5.1%	10.6%	21.4%	32.5%	13.1%	18.3%	21.4%	14.6%	-53.6%	-21.1%	-20.2%	-14.6%	-14.5%	0.5%	-1.5%	2.5%	-13.1%	-12.7%	-22.8%	-9.4%	24.2%	4.0%	-2.9%	8.1%	2.0%	11.4%	2.3%	9.9%
Other income	4	4	7	8	3	6	3	1	1	1	1	1	1	2	2	2	1	2	2	8	2	0	1	3	3	2	1	2	2	1	1	2	1	1	2	2	2	10
Interest	0	—	1	1	1	1	0	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Depreciation	1	2	1	1	2	2	1	2	2	2	2	2	2	2	2	2	2	2	2	2	2	3	5	2	2	3	3	3	3	4	4	4	4	4	4	4	4	4
Profit before tax	25	32	17	33	29	35	12	24	19	34	4	11	26	43	17	25	31	22	-49	-13	-21	-18	-19	2	-1	2	-3	-18	-28	-13	38	3	-7	9	1	13	1	21
Tax	9	11	6	12	10	12	5	9	6	11	1	4	8	14	9	8	10	7	-16	-5	24	0	0	0	1	0	0	0	0	0	0	0	0	0	0	3	0	5
Net profit	16	21	11	21	18	23	7	15	13	22	3	7	18	28	8	17	21	15	-33	-8	-45	-18	-19	2	-1	2	-3	-18	-28	-13	38	3	-7	9	1	11	1	16
EPS ₹	6.49	8.31	4.46	8.52	7.39	9.17	2.91	6.11	5.19	8.83	1.05	2.93	7.01	11.33	3.34	6.70	8.43	5.97	-13.20	-3.26	-18.05	-7.08	-7.43	0.71	-0.49	0.61	-1.03	-7.04	-11.18	-5.36	15.25	1.09	-2.68	3.47	0.22	4.23	0.31	6.39
Revenue YoY	—	—	—	—	23.7%	18.5%	15.2%	12.5%	11.6%	19.8%	22.0%	11.8%	24.8%	14.0%	29.4%	24.0%	17.9%	15.8%	-27.5%	-33.6%	-33.2%	-31.6%	3.4%	37.1%	16.5%	13.4%	20.3%	0.4%	-0.9%	-9.0%	47.7%	5.0%	11.9%	33.6%	-5.8%	5.7%	7.7%	3.9%
Profit YoY	—	—	—	—	13.8%	10.3%	-34.6%	-28.3%	-29.8%	-3.6%	-64.1%	-52.1%	35.2%	28.2%	219.9%	128.8%	20.3%	-47.2%	-495.3%	-148.7%	-314.0%	-218.5%	—	—	—	—	—	-1094.4%	—	-982.2%	—	—	—	—	-98.5%	288.6%	—	84.1%

Returns & margins

trailing-twelve-month, per quarter

showing latest 8 of 32 periods

	DEC '18	MAR '19	JUN '19	SEP '19	DEC '19	MAR '20	JUN '20	SEP '20	DEC '20	MAR '21	JUN '21	SEP '21	DEC '21	MAR '22	JUN '22	SEP '22	DEC '22	MAR '23	JUN '23	SEP '23	DEC '23	MAR '24	JUN '24	SEP '24	DEC '24	MAR '25	JUN '25	SEP '25	DEC '25	MAR '26	JUN '26	SEP '26
ROE	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	16.9%	20.2%	16.9%	22.6%	23.3%	21.3%	22.7%	13.5%	12.1%	14.3%	15.0%	23.8%	24.9%	25.1%	21.5%	19.4%	20.2%
ROCE	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	23.1%	27.3%	22.9%	30.4%	31.8%	29.0%	31.0%	18.8%	16.4%	19.6%	20.5%	32.2%	33.8%	34.5%	29.4%	26.8%	28.5%
Net margin	0.0%	0.0%	0.0%	1.8%	5.0%	6.1%	8.4%	9.9%	9.5%	11.5%	10.7%	9.0%	7.8%	7.6%	8.3%	10.2%	11.6%	9.9%	12.5%	13.4%	11.6%	12.5%	6.9%	5.5%	6.0%	6.7%	9.9%	9.9%	9.2%	8.2%	7.0%	6.8%
EBITDA margin	11.6%	9.8%	12.6%	14.2%	13.6%	14.5%	13.9%	14.1%	13.8%	16.7%	15.4%	13.4%	11.3%	10.7%	11.4%	13.5%	15.1%	16.5%	19.2%	19.0%	16.3%	14.2%	11.2%	10.4%	13.4%	14.8%	16.0%	15.9%	13.2%	11.5%	9.5%	9.6%
Debt / equity	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Interest coverage	—	—	324.77	198.40	129.33	100.96	97.14	100.53	95.18	117.60	105.78	90.51	81.43	87.49	111.03	158.80	195.55	210.55	298.02	221.77	140.60	185.48	116.63	112.74	187.25	108.10	119.95	112.67	88.07	57.17	40.90	36.15
Asset turnover	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	1.01	1.06	1.02	1.08	1.04	1.09	1.20	1.29	1.20	1.30	1.13	1.22	1.24	1.35	1.14	1.22	1.19

Balance sheet

equity vs borrowings over time · ₹ crore

showing latest 6 of 9 periods

	SEP '22	MAR '23	SEP '23	MAR '24	SEP '24	MAR '25	SEP '25	MAR '26	SEP '26
Share capital	5	5	5	5	5	5	5	5	5
Other equity / reserves	539	584	650	707	674	765	794	868	874
Total equity	544	589	655	712	679	770	799	873	879
Borrowings	0	0	0	0	0	0	0	0	0
Current liabilities	342	384	435	357	475	703	777	982	1,190
Non-current liabilities	11	12	11	9	87	45	38	134	123
Total assets	896	985	1,102	1,078	1,241	1,518	1,615	1,989	2,191
Property, plant & equipment	69	69	65	60	67	64	40	117	99
Capital work-in-progress	3	1	1	0	0	0	0	0	16
Investments	0	0	0	53	0	0	0	0	0
Inventories	161	190	267	228	382	548	779	1,027	1,035
Receivables	89	108	130	153	150	185	220	214	285
Cash & equivalents	470	500	520	506	497	536	399	448	574

Cash flow

annual · ₹ crore · line = free cash flow

	FY22	FY23	FY24	FY25	FY26
Cash from operations	101	58	93	65	-15
Cash from investing	5	18	22	31	19
Cash from financing	-9	-24	-44	-66	-92
Capex	10	9	11	2	4
Free cash flow	91	50	82	64	-19
Dividends paid	5	20	40	60	80

Where the assets sit

Sep '26 · ₹ crore

Fixed assets (PPE)

₹99 cr5%

CWIP

₹16 cr1%

Inventories

₹1,035 cr47%

Receivables

₹285 cr13%

Cash & equivalents

₹574 cr26%

Other assets

₹183 cr8%

Peer comparison

largest in Unclassified · this company in bold

Company	Market cap ₹cr	Price	P/E	P/B	ROE
Avantel Limited	36,86,04,549	138.69	—	1059360.68	0.0%
Ducol Organics And Colours Limited	19,55,275	120.00	—	20089.13	0.0%
Jio Platforms Limited	12,57,181	1,406.40	—	3.57	—
SBI Funds Management Limited	1,01,750	499.55	—	—	—
Tamilnadu Telecommunication Limited	91,314	9.93	—	—	—
Manipal Health Enterprises Limited	76,294	646.70	—	—	—
INDO-MIM Limited	59,042	1,219.50	—	—	—
AvenuesAI Limited	45,138	129.25	153.6	9.51	6.2%
Dhoot Transmission Limited	32,761	1,601.60	—	8.11	—
3M India Limited	31,071	27,570.00	53.8	17.57	32.7%
AstraZeneca Pharma India Limited	15,934	6,373.50	89.7	18.13	20.2%

StoxGud checklist: Bearish setup · 3/10

Price above 50-day average
Price above 200-day average
50-day average above 200-day (uptrend)
RSI in healthy 40–70 zone
Positive 1-year return
Return on equity above 15%
Debt to equity below 1
Revenue growing year on year
Net profit margin above 10%
P/E below industry median

A rules-based screen of trend, momentum, quality and valuation. Educational only — not a buy or sell recommendation.

Returns & technicals

1 month+7.7%

6 months-25.4%

1 year-31.8%

3Y CAGR+10.8%

5Y CAGR+16.2%

10Y CAGR+20.6%

50-day avg₹6,418.05

200-day avg₹7,870.44

RSI (14)72

FAQs

What is the share price of AstraZeneca Pharma India Limited?

AstraZeneca Pharma India Limited (ASTRAZEN) closed at ₹6,373.50 on NSE on 06 Nov 2026.

What is the market cap of AstraZeneca Pharma India Limited?

₹15,934 crore at the latest close.

What is the P/E ratio of AstraZeneca Pharma India Limited?

89.7, on trailing-twelve-month earnings from its filings.

How fast is AstraZeneca Pharma India Limited growing?

AstraZeneca Pharma India Limited: revenue has compounded at 31.4% a year over three years; net profit at 23.6% a year. Latest-quarter revenue is up 30.4% year on year, profit up 15.0%.

How profitable is AstraZeneca Pharma India Limited?

On a trailing-twelve-month basis return on equity is 20.2%, return on capital employed 28.5%, operating margin 9.6%, net margin 6.8%.

How much debt does AstraZeneca Pharma India Limited have?

AstraZeneca Pharma India Limited is debt-free: debt to equity is 0.00 with borrowings of ₹0 cr against cash of ₹574 cr (balance sheet of 2026-09-30). Operating profit covers interest 36.1 times.

Financials parsed from AstraZeneca Pharma India Limited's own XBRL filings to NSE (standalone), ₹ crore unless marked. Quarterly from MAR '17, annual from FY19, balance sheet from Sep '22. * = derived (full year or half year minus earlier quarters). Information only, not investment advice.